Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 18/20 | 0.60 |
| ▸ | MC3R | P41968 | 7/20 | 0.60 |
| ▸ | MC5R | P33032 | 6/20 | 0.54 |
| ▸ | PRCP | P42785 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13391278 | 1.00 | MC4R (0.60) | MC4RMC3RMC5RPRCP | |
| SCHEMBL13379970 | 1.00 | MC4R (0.60) | MC4RMC3RMC5RPRCP | |
| SCHEMBL3112500 | 1.00 | MC4R (0.60) | MC4RMC3RMC5RPRCP | |
| SCHEMBL13847931 | 0.91 | PRCP (0.51) | MC4RMC3RMC5RPRCP | |
| SCHEMBL13379893 | 0.91 | PRCP (0.51) | MC4RMC3RMC5RPRCP | |
| SCHEMBL13390891 | 0.91 | PRCP (0.51) | MC4RMC3RMC5RPRCP | |
| SCHEMBL14623196 | 0.85 | MC4R (0.67) | MC4RMC3RMC5RPRCP | |
| SCHEMBL91100 | 0.84 | MC4R (0.82) | MC4RMC3RMC5RPRCP | |
| SCHEMBL70501 | 0.84 | MC4R (0.82) | MC4RMC3RMC5RPRCP | |
| SCHEMBL31737049 | 0.84 | MC4R (0.82) | MC4RMC3RMC5RPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700778-B2 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1385506-B1 | ACYLATED PIPERIDINE DERIVATES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7012084-B2 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20060025442-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | disclosed |
| US-20040092501-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025442-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | MC4R 1/4885MC3R 3/4885MC5R 2/4885 |
| US-20040092501-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | MC4R 1/4885MC3R 3/4885MC5R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.